JP2020517255A5 - - Google Patents

Download PDF

Info

Publication number
JP2020517255A5
JP2020517255A5 JP2019556884A JP2019556884A JP2020517255A5 JP 2020517255 A5 JP2020517255 A5 JP 2020517255A5 JP 2019556884 A JP2019556884 A JP 2019556884A JP 2019556884 A JP2019556884 A JP 2019556884A JP 2020517255 A5 JP2020517255 A5 JP 2020517255A5
Authority
JP
Japan
Prior art keywords
nucleic acid
viral vector
acid sequence
engineered
sequence encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019556884A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517255A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/028607 external-priority patent/WO2018195449A1/en
Publication of JP2020517255A publication Critical patent/JP2020517255A/ja
Publication of JP2020517255A5 publication Critical patent/JP2020517255A5/ja
Priority to JP2022145178A priority Critical patent/JP7214915B2/ja
Pending legal-status Critical Current

Links

JP2019556884A 2017-04-21 2018-04-20 Pcsk9遺伝子の認識配列に特異的な操作されたメガヌクレアーゼ Pending JP2020517255A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022145178A JP7214915B2 (ja) 2017-04-21 2022-09-13 Pcsk9遺伝子の認識配列に特異的な操作されたメガヌクレアーゼ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762488403P 2017-04-21 2017-04-21
US62/488,403 2017-04-21
US201762516966P 2017-06-08 2017-06-08
US62/516,966 2017-06-08
PCT/US2018/028607 WO2018195449A1 (en) 2017-04-21 2018-04-20 Engineered meganucleases specific for recognition sequences in the pcsk9 gene

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022145178A Division JP7214915B2 (ja) 2017-04-21 2022-09-13 Pcsk9遺伝子の認識配列に特異的な操作されたメガヌクレアーゼ

Publications (2)

Publication Number Publication Date
JP2020517255A JP2020517255A (ja) 2020-06-18
JP2020517255A5 true JP2020517255A5 (enExample) 2021-05-27

Family

ID=62117064

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019556884A Pending JP2020517255A (ja) 2017-04-21 2018-04-20 Pcsk9遺伝子の認識配列に特異的な操作されたメガヌクレアーゼ
JP2022145178A Active JP7214915B2 (ja) 2017-04-21 2022-09-13 Pcsk9遺伝子の認識配列に特異的な操作されたメガヌクレアーゼ
JP2023005733A Pending JP2023058509A (ja) 2017-04-21 2023-01-18 Pcsk9遺伝子の認識配列に特異的な操作されたメガヌクレアーゼ
JP2024231599A Pending JP2025066725A (ja) 2017-04-21 2024-12-27 Pcsk9遺伝子の認識配列に特異的な操作されたメガヌクレアーゼ

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022145178A Active JP7214915B2 (ja) 2017-04-21 2022-09-13 Pcsk9遺伝子の認識配列に特異的な操作されたメガヌクレアーゼ
JP2023005733A Pending JP2023058509A (ja) 2017-04-21 2023-01-18 Pcsk9遺伝子の認識配列に特異的な操作されたメガヌクレアーゼ
JP2024231599A Pending JP2025066725A (ja) 2017-04-21 2024-12-27 Pcsk9遺伝子の認識配列に特異的な操作されたメガヌクレアーゼ

Country Status (11)

Country Link
US (4) US11680254B2 (enExample)
EP (2) EP4269596A3 (enExample)
JP (4) JP2020517255A (enExample)
KR (2) KR102620399B1 (enExample)
CN (2) CN117264929A (enExample)
AU (2) AU2018254576B2 (enExample)
CA (1) CA3060112A1 (enExample)
ES (1) ES2953153T3 (enExample)
IL (2) IL270020B2 (enExample)
MX (2) MX2019012452A (enExample)
WO (1) WO2018195449A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3969577A4 (en) * 2019-04-15 2023-10-04 The Trustees of The University of Pennsylvania COMPOSITIONS FOR REGULATING AND SELF-INACTIVATING ENZYME EXPRESSION AND METHODS FOR MODULATING OFF-TARGET ENZYME ACTIVITY
US20220195407A1 (en) 2019-05-07 2022-06-23 Precision Biosciences, Inc. Optimization of engineered meganucleases for recognition sequences
US20230167464A1 (en) * 2020-04-27 2023-06-01 The Trustees Of The University Of Pennsylvania Compositions and methods for reducing nuclease expression and off-target activity using a promoter with low transcriptional activity
EP4143308A4 (en) * 2020-04-27 2024-06-26 The Trustees of The University of Pennsylvania COMPOSITIONS AND METHODS FOR REDUCING NUCLEASE EXPRESSION AND OFF-TARGET ACTIVITY USING A PROMOTER WITH LOW TRANSCRIPTION ACTIVITY
WO2021231259A1 (en) 2020-05-11 2021-11-18 Precision Biosciences, Inc. Self-limiting viral vectors encoding nucleases
AU2021270447A1 (en) 2020-05-12 2023-01-05 The Trustees Of The University Of Pennsylvania Compositions for DRG-specific reduction of transgene expression
EP4236975A1 (en) 2020-10-29 2023-09-06 The Trustees of The University of Pennsylvania Aav capsids and compositions containing same
EP4244342A1 (en) * 2020-11-12 2023-09-20 Precision BioSciences, Inc. Engineered meganucleases having specificity for recognition sequences in the dystrophin gene
TW202309066A (zh) 2021-04-27 2023-03-01 賓州大學委員會 衍生自豬的腺相關病毒衣殼及其用途
US20250295807A1 (en) 2021-11-15 2025-09-25 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
WO2024015966A2 (en) 2022-07-15 2024-01-18 The Trustees Of The University Of Pennsylvania Recombinant aav having aav clade d and clade e capsids and compositions containing same
WO2025122552A1 (en) * 2023-12-04 2025-06-12 The Trustees Of The University Of Pennsylvania In silico prediction tool for meganuclease off-target sites

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5652224A (en) * 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US6555674B2 (en) 2000-08-09 2003-04-29 Nsgene A/S JeT promoter
ES2602352T3 (es) 2001-12-17 2017-02-20 The Trustees Of The University Of Pennsylvania Secuencias de serotipo 8 de virus adenoasociado (VAA), vectores que las contienen y usos de las mismas
EP1590468A2 (en) 2003-01-28 2005-11-02 Cellectis Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
ES2626025T3 (es) 2005-10-18 2017-07-21 Precision Biosciences Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas
ES2366974T3 (es) * 2006-05-05 2011-10-27 Isis Pharmaceuticals, Inc. Compuestos y procedimientos para modular la expresión de sglt2.
AU2013201688B2 (en) * 2006-11-07 2016-03-03 Merck Sharp & Dohme Llc Antagonists of PCSK9
AU2013203677C1 (en) * 2007-08-23 2017-05-25 Amgen Inc. Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)
CA2603615A1 (en) 2007-09-21 2009-03-21 Patrick Labonte Methods of reducing viral infection and kits therefore
EP2660317B1 (en) 2007-10-31 2016-04-06 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
US7928189B2 (en) * 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
DK2313498T3 (en) 2008-07-14 2017-05-22 Prec Biosciences Inc RECOGNITION SEQUENCES FOR I-CREI-DERIVED MECHANUCLEASES AND APPLICATIONS THEREOF
EP2180058A1 (en) * 2008-10-23 2010-04-28 Cellectis Meganuclease recombination system
AU2013273674B2 (en) * 2009-09-03 2015-11-05 Pfizer Vaccines Llc PCSK9 vaccine
DK3489366T3 (da) 2011-06-01 2020-02-24 Prec Biosciences Inc Fremgangsmåder og produkter til produktion af manipulerede mammale cellelinier med forstærkede transgener
US20150366997A1 (en) * 2012-12-07 2015-12-24 Shire Human Genetics Therapies, Inc. COMPOSITIONS AND METHODS FOR mRNA DELIVERY
US10329574B2 (en) * 2013-03-12 2019-06-25 E I Du Pont De Nemours And Company Methods for the identification of variant recognition sites for rare-cutting engineered double-strand-break-inducing agents and compositions and uses thereof
CN107995927B (zh) * 2013-06-17 2021-07-30 布罗德研究所有限公司 用于肝靶向和治疗的crispr-cas系统、载体和组合物的递送与用途
EA201691587A1 (ru) * 2014-02-11 2017-01-30 Элнилэм Фармасьютикалз, Инк. КОМПОЗИЦИИ НА ОСНОВЕ iRNA ДЛЯ КЕТОГЕКСОКИНАЗЫ (KHK) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2015164778A1 (en) * 2014-04-25 2015-10-29 The Trustees Of The University Of Pennysylvania Ldlr variants and their use in compositions for reducing cholesterol levels
WO2015175642A2 (en) 2014-05-13 2015-11-19 Sangamo Biosciences, Inc. Methods and compositions for prevention or treatment of a disease
WO2017044649A1 (en) * 2015-09-08 2017-03-16 Precision Biosciences, Inc. Treatment of retinitis pigmentosa using engineered meganucleases
EP4108255A1 (en) * 2015-10-05 2022-12-28 Precision Biosciences, Inc. Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene

Similar Documents

Publication Publication Date Title
JP2020517255A5 (enExample)
JP2019530462A5 (enExample)
JP2018537087A5 (enExample)
JP2015096070A5 (enExample)
JP2018515096A5 (enExample)
JP2018520997A5 (enExample)
JP2023179436A5 (enExample)
JP2017018125A5 (enExample)
JP2020508667A5 (enExample)
IL318395A (en) Recombinant viral particles with altered tropism, and their uses for targeted introduction of genetic material into human cells
Ferrer-Miralles et al. Biological activities of histidine-rich peptides; merging biotechnology and nanomedicine
JP2016052331A5 (enExample)
JP2020022459A5 (enExample)
JP2014503206A5 (enExample)
JP2018537089A5 (enExample)
JP2013521789A5 (enExample)
JP2014239686A5 (enExample)
JP2016533332A5 (enExample)
JP2016521539A5 (enExample)
WO2006063101A3 (en) Vaccines for the rapid response to pandemic avian influenza
JP2014198050A5 (enExample)
JP2024180560A5 (enExample)
JP2003503355A5 (enExample)
CN110892067A (zh) 热稳定性提高的phi29DNA聚合酶突变体
CN116113702A (zh) 一种融合蛋白及其用途